Washington Report Articles
The U.S. Food and Drug Administration (FDA) is taking critical actions to advance development of novel coronavirus medical countermeasures.
The awards establish and provide up to seven years of support for three Immune Mechanisms of Protection Against Mycobacterium Tuberculosis (IMPAc-TB) Centers to elucidate the immune responses needed to protect against Mtb infection.
A final rule that went into effect Nov. 4 strengthens the Centers for Medicare and Medicaid Services’ ability to stop fraud before it happens.
The Centers for Medicare and Medicaid Services (CMS) has finalized a rule to update and modernize the Programs of All-Inclusive Care for the Elderly (PACE) that reflects updates based upon best practices in caring for frail and elderly individuals.
The U.S. Food and Drug Administration (FDA) released guidelines on the studies companies need to conduct to show their biosimilar is interchangeable with a biologic.
The Centers for Medicare and Medicaid Services (CMS) published a final rule for calculating state Medicaid disproportionate share hospital (DSH) cuts in the amount of $4 billion in 2020 and $8 billion for each subsequent year through 2025.
The National Institutes of Health (NIH) has awarded $945 million to battle addiction and chronic pain.
The U.S. Department of Health and Human Services released an additional $487 million to supplement first-year funding through its State Opioid Response grant program.
The U.S. Food and Drug Administration has issued draft guidance to overcome obstacles to increasing enrollment diversity in clinical trials.
The Centers for Medicare and Medicaid Innovation is introducing new pay models that will shift primary care from fee-for-service payments to a global fee model under which clinicians and hospitals could assume varying amounts of risk.
The U.S. Food and Drug Administration (FDA) has awarded 12 new clinical trial research grants to principal investigators from academia and industry totaling more than $18 million over the next four years to enhance the development of medical products for patients with rare diseases.
The Centers for Medicare and Medicaid Services has revised Chapter 13 of the Medicare Program Integrity Manual to include instructions, policies and procedures that Medicare Administrative Contractors (MACs) use to administer the Medicare fee-for-service program.
